The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2)
Official Title: A Phase 2 Open-Label Clinical Trial of ADP-A2M4CD8 in Subjects With Advanced Esophageal or Esophagogastric Junction Cancers
Study ID: NCT04752358
Brief Summary: This study will investigate the efficacy of ADP-A2M4CD8 T-cell therapy in subjects who have the appropriate human leukocyte antigen (HLA) and tumor antigen status and whose esophageal or esophagogastric junction (EGJ) cancer expresses the MAGE-A4 protein.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
City of Hope National Medical Center, Duarte, California, United States
University of Chicago Medicine, Chicago, Illinois, United States
Washington University School of Medicine- Siteman Cancer Center, Saint Louis, Missouri, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
Providence Cancer Institute Franz Clinic, Portland, Oregon, United States
University Of Texas, MD Anderson Cancer Center, Houston, Texas, United States
University Of Wisconsin Clinical Science Center, Madison, Wisconsin, United States
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
McGill University Health Centre Glen Site, Montreal, Quebec, Canada
Hospital Universitari Vall d'Hebron, la Vall d'Hebron, Barcelona, Spain
Hospital Universitario 12 de Octubre, Córdoba, Madrid, Spain
Hospital Clinico Universitario de Valencia, Ibáñez, Valencia, Spain
Hospital Fundacion Jimenez Diaz, Madrid, , Spain
Hospital Universitario Madrid Sanchinarro (CIOCC), Madrid, , Spain
Clinica Universidad de Navarra, Navarro, , Spain
Hospital Universitario Virgen del Rocio, Sevilla, , Spain